ClinicalTrials.gg
CompletedNCT02432833STEADYUpdated Apr 13, 2018

Multicentre, Open Label, Randomized, Two-arm, Parallel-group Study to Assess Efficacy and Safety of ENVARSUS® Compared With Tacrolimus Used as Per Current Clinical Practice in the Initial Maintenance Setting in de Novo Kidney Transplant Patients

A Phase 4 interventional study of ENVARSUS® and PROGRAF® in End Stage Renal Disease, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-13.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
428
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing tacrolimus in Kidney Failure, Chronic — 1 open to participants now, 2 under way, 1 of them phase 3. Tacrolimus · Kidney Failure, Chronic.

Enrollment
Largest of 13
428 · median 46
Started
2015
the only one that year
Phase 4
10 of 13
none open now
Registered
8th of 13
by date
Lead sponsor
1 of 13
Chiesi Farmaceutici S.p.A.

Among the 13 studies testing tacrolimus in Kidney Failure, Chronic, this one has the largest enrollment, is the only one that started in 2015, is one of 10 in phase 4, and was the 8th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

1 of the 13 studies testing tacrolimus in Kidney Failure, Chronic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About tacrolimus

Tacrolimus: first FDA approval 1994 (PROGRAF), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing tacrolimus in Kidney Failure, Chronic, or all of them as a file.
02

Study summary

The purpose of the study is to compare tacrolimus dosing of the new Envarsus®-based immunosuppressive regimen with current clinical practice (Prograf or Advagraf) over 6 months following de novo renal transplantation in a real-life setting in different European Countries.

Read the detailed description

This is a Multicentre, Open label, Randomized, Two-arm, parallel-group study to assess efficacy and safety of Envarsus® compared with tacrolimus used as per current clinical practice in the initial maintenance setting in de novo kidney transplant patients. The study will be conducted in approximately 10 european countries.

03

Conditions studied

  • End Stage Renal Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient's signed obtained prior to any study-related procedure;
  2. Adult men and women at least 18 years of age with end-stage renal disease who are recipients (or will be recipients) of a kidney transplant from a living or deceased donor;
  3. No known to the administration of tacrolimus, other macrolides and study drugs ;
  4. Patients must agree to use a highly reliable method of ;
  5. Donor-recipient negative cross match test, and compatible AB0 blood type;
  6. Able to swallow tablets and capsules

Exclusion criteria

Exclusion Criteria:

  1. Recipient of any transplanted organ other than kidney;
  2. Recipient of a previous renal transplant;
  3. Recipient of a kidney from a donor after cardiac death;
  4. Recipient of a kidney from an AB0 incompatible or positive cross-match donor;
  5. Current (not older than 3 months) anti-HLA Panel Reactive Antibody (PRA) levels higher than 30%. Whenever PRA, either complement-dependent cytotoxicity-PRA or calculated PRA , is not available, patients who are positive on solid-phase screening assay for anti-HLA antibodies must not be enrolled;
  6. Recipient of a kidney with a cold ischemia time of ≥ 30 hours;
  7. White blood cells count ≤ 2.8x109 cells/L unless >1.0x109/L;
  8. count \< 50 x109 cells/L;
  9. or AST levels >3 times the normal upper limit during the 30 days prior transplant procedure;
  10. Current abuse of drugs or alcohol;
  11. Incapable of understanding purpose and risk of study, unable to give written or unwilling to comply with study protocol;
  12. Treatment with any other agent in the 30 days prior to enrolment;
  13. Kidney recipients and/or donors positive for (HCV-RNA positive or HCV-Ab positive respectively);
  14. Kidney recipients and/or donors positive for (HBV-DNA or HBS-Ag positive);
  15. Recipients positive for ;
  16. Patient or donor with current diagnosis or history of within the past 5 years except basal or non- squamous cell carcinoma of the skin successfully treated;
  17. Uncontrolled concomitant infection, systemic infection requiring treatment or any other unstable condition that could interfere with study objectives;
  18. Severe diarrhoea, vomiting, active peptic ulcer or GI disorder that may affect absorption of tacrolimus;
  19. Known to tacrolimus other macrolides and study drugs ;
  20. Pregnant or lactating women and all women physiologically capable of becoming pregnant (i.e. women of ) UNLESS are willing to use reliable methods of
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
428 participants (actual)

Study arms

  • Experimental
    Envarsus® (tacrolimus)

    prolonged-release tablets once daily and orally

    Drug: ENVARSUS®

  • Active comparator
    Prograf or Advagraf

    Prograf® hard capsules, twice daily, oral formulation or Advagraf® prolonged-release hard capsules, once daily, oral formulation

    Drug: PROGRAF® · Drug: ADVAGRAF®

Interventions

  • Envarsus® tablets, once daily, oral formulation. Prolonged -release formulation of tacrolimus

  • Prograf® hard capsules, twice daily, oral formulation

  • Advagraf® prolonged-release hard capsules, once daily, oral formulation

06

What researchers measure

Primary outcomes

  1. Tacrolimus total daily dose (TDD) from week 3 to month 6

    Time frame: from week 3 to month 6

Secondary outcomes

  1. Tacrolimus blood trough level (TL).

    Time frame: from screening to months 6

  2. number of dose adjustment

    Time frame: from screening to months 6

  3. Occurrence of treatment failure

    Time frame: from screening to months 6

  4. Delayed graft function

    Time frame: from screening to months 6

  5. Acute rejection requiring treatment

    Time frame: from screening to months 6

  6. Consumption of concomitant immunosuppressant medications

    Time frame: from screening to months 6

  7. Treatment discontinuation

    Time frame: from screening to months 6

07

Study locations

1 site
  • Chiesi farmaceutici Spa
    Parma, 43123, Italy
08

References and documents

Publications

  • Budde K, Rostaing L, Maggiore U, Piotti G, Surace D, Geraci S, Procaccianti C, Nicolini G, Witzke O, Kamar N, Albano L, Buchler M, Pascual J, Gutierrez-Dalmau A, Kuypers D, Wekerle T, Glyda M, Carmellini M, Tisone G, Midtvedt K, Wennberg L, Grinyo JM. Prolonged-Release Once-Daily Formulation of Tacrolimus Versus Standard-of-Care Tacrolimus in de novo Kidney Transplant Patients Across Europe. Transpl Int. 2022 Mar 21;35:10225. doi: 10.3389/ti.2021.10225. eCollection 2022. PubMed 36017158 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2015, a primary completion of Jan 2017 and a completion of Jan 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2015
First posted
May 4, 2015
Start
May 2015
Primary completionActual
Jan 24, 2017
CompletionActual
Jan 24, 2017
Last update
Apr 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02432833
Responsible party
Sponsor
First posted
May 4, 2015
Start date
May 2015
Primary completion
Jan 24, 2017
Completion
Jan 24, 2017
Last update
Apr 13, 2018

Study contacts

Klemens Budde, MD
principal investigator · Berlin, Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tacrolimus

Start the discussion